Flucloxacillin in the treatment of infectious conditions in children.
A multi-centre study was carried out in 107 children with skin and soft-tissue infections (46) or upper respiratory tract infections (61) to assess the effectivness of flucloxacillin (125 mg. q.d.s. for 5 days). Swabs were taken from the lesion sites before and after treatment for bacteriological assessment and sensitivity of the isolated organisms. The clinical success rate achieved was 93% in skin and soft-tissue infections and 94% in upper respiratory tract infections and these results correlate closely with the bacteriological findings. The main causative organism in the skin and soft-tissue infections was Staph. aureus which was resistant to benzyl penicillin and to ampicillin in all but 2 cases. All strains proved sensitive to flucloxacillin. Minimal side-effects were reported and the syrup presentation was well accepted.
D000284:Administration, Oral; D002648:Child; D002675:Child, Preschool; D003023:Cloxacillin / Q000031:analogs & derivatives*; D005436:Floxacillin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007169:Impetigo / Q000188:drug therapy*; D007223:Infant; D011379:Prognosis; D012141:Respiratory Tract Infections / Q000188:drug therapy; D012874:Skin Diseases, Infectious / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013210:Staphylococcus / Q000302:isolation & purification; D013290:Streptococcal Infections / Q000188:drug therapy*
D005436:Floxacillin; D003023:Cloxacillin